Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 13th. Analysts expect Zevra Therapeutics to post earnings of ($0.21) per share and revenue of $16.96 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Up 1.0%

Zevra Therapeutics stock opened at $7.87 on Monday. The stock has a market capitalization of $430.32 million, a PE ratio of -3.99 and a beta of 1.87. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The business has a 50 day simple moving average of $7.52 and a 200-day simple moving average of $8.07. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Canaccord Genuity Group boosted their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $22.29.

Insider Buying and Selling

In related news, Director John B. Bode bought 10,000 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was bought at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at $318,400. This represents a 33.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the sale, the executive vice president now owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. The trade was a 26.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by corporate insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.